Exact Sciences acquires OmicEra Diagnostics

The OmicEra-team © OmicEra

The Planegg-based diagnostics startup OmicEra specializes in large-scale protein analyses. Now it has been acquired for $15 million by Exact Sciences, a U.S. cancer diagnostics company.

Founded in 2019 by a team of leading proteomics scientists at the Max Planck Institute of Biochemistry in Martinsried, Germany, OmicEra Diagnostics offers proteomic analyses of human samples based on mass spectrometry. In analyzing the samples, the start-up also uses innovative AI technologies such as machine learning algorithms and biostatistical methods. OmicEra's team of proteomics scientists and artificial intelligence experts aims to revolutionize diagnostic methods using mass spectrometry-based high-end proteomics. In this way, the startup wants to discover more reliable and valuable biomarkers for early cancer detection and ultimately improve patient health.

Exact Sciences is also working on new solutions in cancer diagnostics. The global U.S. company, based in Madison, Wisconsin, is a provider of cancer screening and diagnostic tests to help individuals before and during their cancer diagnosis and treatment.

As part of Exact Sciences' research and development team, OmicEra Diagnostics will apply its solutions and expertise to help Exact Sciences discover new biomarkers for early cancer detection.